Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30004395HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30005737HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028946HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028947HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028948HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028949HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028950HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028951HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TVIS30028952HIVENSG00000167325.15protein_codingRRM1NoNo6240E9PL69
P23921
TCGA Plot Options
Drug Information
GeneRRM1
DrugBank IDDB01280
Drug NameNelarabine
Target IDBE0000325
UniProt IDP23921
Regulation Typeinhibitor
PubMed IDs18035189; 18473971
CitationsBuie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther. 2007 Sep;29(9):1887-99.@@Curbo S, Karlsson A: Nelarabine: a new purine analog in the treatment of hematologic malignancies. Rev Recent Clin Trials. 2006 Sep;1(3):185-92.
GroupsApproved; Investigational
Direct ClassificationPurine nucleosides
SMILESCOC1=NC(N)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Pathways
PharmGKBPA164752425
ChEMBLCHEMBL1201112